Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies (Q41168197)

27 September 2017

Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies (English)

1 reference

27 September 2017

1 reference

Matteo Monami

1

1 reference

27 September 2017

Benedetta Ragghianti

2

1 reference

27 September 2017

Stefania Zannoni

3

1 reference

27 September 2017

Valentina Vitale

4

1 reference

27 September 2017

Besmir Nreu

5

1 reference

27 September 2017

Edoardo Mannucci

6

1 reference

27 September 2017

26 March 2015

1 reference

27 September 2017

1 reference

27 September 2017

53

1 reference

27 September 2017

1

1 reference

27 September 2017

35-40

1 reference

https://scigraph.springernature.com/pub.10.1007/s00592-015-0732-1

27 September 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

Hypoglycemia with intensive insulin therapy after cardiac surgery: predisposing factors and association with mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-015-0732-1

10.1007/S00592-015-0732-1

21 January 2018

Identifiers

DOI

1 reference

27 September 2017

1 reference